How Often Are Uterine Polyps Cancerous?

Roughly 3 in every 100 uterine polyps removed and examined under a microscope turn out to be cancerous, according to large pooled analyses involving tens of thousands of women. That number is low enough that most polyps are benign growths of endometrial tissue, but high enough that doctors take them seriously, especially in certain patient groups where the odds climb. The story behind that average matters more than the average itself, because individual risk varies widely depending on age, symptoms, medication history, and polyp characteristics.

What the Pooled Data Show

Two large meta-analyses have tried to pin down a single overall malignancy rate by combining results from many individual studies. One pooled 51 studies covering over 35,000 women and found a malignancy rate of about 2.7%.¹ A more recent analysis of 20 studies and over 11,000 patients arrived at almost exactly the same figure: 2.75% malignant.² That second analysis also found that an additional 1.8% had atypical hyperplasia, a precancerous condition, and about 5% had hyperplasia without atypia, which is a less concerning overgrowth of the lining.

Individual studies land all over the map. A smaller single-center study of 300 polyps found just 1.3% were malignant.³ Another study of about 500 polyps reported only 0.8% cancerous, though a quarter of them showed some form of hyperplasia.⁴ The variation happens because different studies include different mixes of patients: some enroll mostly younger premenopausal women, others focus on postmenopausal women with bleeding, and the risk profile in those groups is very different. The pooled figure of roughly 3% is the best single number available, but it hides a lot of important detail.

Menopausal Status and Bleeding Change the Odds Substantially

If one factor dominates the risk picture, it is whether you have gone through menopause. In premenopausal women, the combined risk of cancer or atypical hyperplasia within a polyp runs around 1% regardless of whether bleeding is present.⁵ That is quite low. After menopause, the numbers start separating. In postmenopausal women without symptoms, the rate was about 1.9% in one large study, but in postmenopausal women with abnormal uterine bleeding it rose to 3.8%.⁵

Another study looking specifically at postmenopausal women found an even starker contrast: among those without bleeding, the vast majority of polyps were benign mucous polyps, and endometrial tumors were found only among women who had vaginal bleeding, at a rate of about 7%.⁶ The practical takeaway is that a polyp discovered incidentally in a premenopausal woman with no symptoms sits at the low end of the risk spectrum. A polyp discovered in a postmenopausal woman who is experiencing unexpected bleeding sits at a meaningfully higher level and warrants faster action.

Does Polyp Size Matter?

This is one of the areas where the evidence is genuinely mixed, and doctors have debated it for years. One study found that polyps at or above about 2.25 cm in length were over thirteen times more likely to be malignant than smaller ones, with 75% sensitivity and 82% specificity at that cutoff.⁷ That sounds like a strong signal, and it has influenced clinical practice: many guidelines recommend removing polyps larger than 2 cm in postmenopausal women even without symptoms.

But another study specifically looking at asymptomatic postmenopausal women compared malignancy rates across several size cutoffs (10 mm, 15 mm, and 20 mm) and found no significant difference at any of them.⁸ The contradiction probably reflects different study populations and sample sizes, but it means size alone is not a reliable way to rule cancer in or out. Most clinicians treat polyp size as one piece of the puzzle rather than a standalone decision tool. A large polyp in a postmenopausal woman with bleeding is concerning on multiple fronts, while a large polyp in a young asymptomatic woman carries far less weight.

Tamoxifen and the Elevated Risk It Carries

Tamoxifen, a drug widely used to treat hormone-receptor-positive breast cancer, is the single most discussed medication-related risk factor for both endometrial polyps and the chance that those polyps will be malignant. Tamoxifen acts as an estrogen blocker in breast tissue but has estrogen-like effects on the uterine lining, stimulating growth.

A large population study found that tamoxifen use nearly quadrupled the risk of developing endometrial polyps and was also independently associated with roughly a fourfold increase in the risk of endometrial cancer.⁹ When polyps do develop in tamoxifen users, they carry an elevated rate of malignant transformation ranging from about 3% to over 10%, compared with well under 1% in the general population by some estimates.¹⁰ A smaller study of 67 polyps in postmenopausal tamoxifen users found 3% were malignant.¹¹

If you are on tamoxifen, your doctor will typically recommend regular monitoring of the uterine lining. A levonorgestrel-releasing intrauterine device (commonly known by brand names like Mirena) has been shown to reduce the rate of endometrial polyps in tamoxifen users, giving a practical prevention option during treatment.¹²

Other Factors That Push Risk Up

Beyond menopausal status and tamoxifen, a few other variables consistently appear in the research. Obesity and older age were both independently associated with premalignant or malignant polyps in a multivariate analysis that controlled for other factors.¹³ Higher fasting glucose and elevated inflammatory markers like CRP have also been flagged as risk factors in at least one study, though these findings are newer and less well replicated.⁷

Women with Lynch syndrome, a hereditary cancer predisposition, face a substantially higher overall risk of endometrial cancer and warrant closer surveillance. In a screening study of Lynch syndrome carriers undergoing annual hysteroscopy, the annual incidence of endometrial cancer was about 3.6%, and polyps appeared at a rate of nearly 11% per year.¹⁴ This is a population where even a “benign-looking” polyp may deserve prompt removal and careful pathologic review.

Can Imaging Tell Whether a Polyp Is Cancerous?

Standard transvaginal ultrasound can detect a polyp reliably, but telling the difference between a benign polyp and a cancerous one on ultrasound alone is difficult. Research into Doppler ultrasound, which measures blood flow patterns, has shown that malignant growths tend to have lower vascular resistance than benign polyps, meaning blood flows through them more freely. One prospective study using contrast-enhanced Doppler found statistically significant differences in blood flow indices between benign polyps and cancers.¹⁵

While Doppler adds useful information, the consensus is that it is not specific enough on its own to replace tissue sampling.¹⁶ The definitive answer still requires removing the polyp, or at least biopsying it, and examining the tissue under a microscope. No imaging technique currently available can confidently rule out malignancy in an endometrial polyp.

When Polyps Disappear on Their Own

Not every polyp needs to be removed surgically. Some polyps, particularly small ones in premenopausal women, regress spontaneously. One study tracking polyps over time found that about 23% regressed without treatment, and all of these were in premenopausal women. Polyps that regressed were smaller at diagnosis, typically under 2 cm, and more common in women under 45.¹⁷ Another study found a lower regression rate of about 6% over a median follow-up of 28 months, also with a trend toward regression in premenopausal women.¹⁸

Evidence-based guidelines estimate that roughly a quarter of polyps may resolve if managed conservatively.¹⁹ The challenge is that waiting carries a small but nonzero risk of missing a cancer, so watchful waiting is typically reserved for small polyps in younger women without symptoms or risk factors. If any bleeding develops during observation, the calculus changes.

How Doctors Decide Whether to Remove a Polyp

Management decisions sit on a spectrum. At one end is watchful waiting, appropriate for small asymptomatic polyps in premenopausal women with no elevated risk factors. At the other end is prompt surgical removal via hysteroscopic polypectomy, the standard procedure for symptomatic polyps or any polyp in a higher-risk patient.

Evidence-based guidelines recommend removal in the following situations:²⁰

Abnormal bleeding: Polypectomy is recommended for all women experiencing abnormal uterine bleeding, regardless of age or polyp size.
Postmenopausal, large polyps: Asymptomatic polyps over 2 cm in postmenopausal women should be removed.
Risk factors present: In both premenopausal and postmenopausal women, the presence of cancer risk factors (obesity, tamoxifen use, Lynch syndrome, diabetes) lowers the threshold for removal.
Small, asymptomatic, low-risk: Removing polyps under 2 cm in asymptomatic postmenopausal women without risk factors has not been shown to improve survival or be cost-effective.

A 2024 Canadian guideline emphasizes that management should be tailored to the individual, taking symptoms, risk profile, and patient preference into account. When patients do not experience symptoms and risk is low, treatment is often not necessary.²¹

Recurrence After Removal

Polyps can come back after they have been removed. The reported recurrence rates vary: one large study found that about 5.6% of polyps recurred after initial removal, and reassuringly, no malignancies developed among those recurrent polyps over a median follow-up of nearly two years.²² Other studies have found higher rates. One reported 8% recurrence at a median of about 42 months.²³ Another found 14% over a longer follow-up.²⁴

Several factors increase the odds of recurrence. The strongest associations have been found with adenomyosis, polycystic ovarian syndrome, obesity (BMI 30 or above), tamoxifen use, and uterine fibroids.²³ A levonorgestrel-releasing intrauterine device dramatically cut recurrence risk in that same study, reducing it by over 95%.²³ This makes the hormonal IUD a practical tool both for preventing recurrence after polypectomy and for protecting the uterine lining in tamoxifen users.

The Hormone Receptor Story Inside Polyps

Endometrial polyps are hormone-sensitive growths, and the pattern of estrogen and progesterone receptors within them turns out to be related to malignancy risk. In benign polyps, the connective tissue (stroma) tends to express estrogen receptors at higher levels than it does in premalignant or malignant polyps. When both estrogen and progesterone receptor expression is absent in the stromal component, the risk of malignancy is significantly elevated.²⁵ This is not something you would know from an ultrasound or clinical exam; it is determined after the polyp is removed and analyzed. But it reinforces the biological link between hormonal signaling gone awry and the transition from benign to malignant.

Recent genomic research has begun mapping the mutations present even in benign endometrial polyps. A 2025 study found that, alongside the expected structural gene changes common in polyps, some polyps carried low-level mutations in well-known cancer genes like KRAS, PIK3CA, and PTEN.²⁶ The presence of these mutations at low levels in benign tissue suggests that polyps may occasionally be early waypoints on a path toward cancer, even if most of them never complete that journey. This is an active area of research, and eventually it could lead to molecular tests that help decide which polyps need removal and which can safely be watched.

How Uterine Polyps Compare to Polyps Elsewhere in the Body

People who hear the word “polyp” often think of colon polyps, where the screening-and-removal strategy is well established because certain types have a clear path to colorectal cancer. Endometrial polyps have a much lower rate of malignant transformation than polyps found in several other organs, including the colon, bladder, and upper airway.²⁷ Cervical polyps, which are sometimes discovered alongside endometrial polyps, are similarly low-risk, found in a few percent of gynecologic exams and only rarely causing trouble beyond occasional spotting.

The relatively low transformation rate in endometrial polyps is part of why management can be conservative in low-risk patients. Unlike colonic adenomas, where “find it, remove it” is the standard approach because progression rates are higher and screening intervals are long, endometrial polyps allow for more nuanced decision-making. That said, the comparison has limits: endometrial cancer is still a serious disease, and the uterine lining cannot be visualized as easily as the colon during a routine exam, which is why symptoms like unexpected bleeding always deserve investigation.

1
PubMed. The risk of malignancy in uterine polyps: A systematic review and meta-analysis
2
PubMed Central. Risks of Malignancy among 11,204 Patients with Endometrial Polyp: A Systematic Review and Meta-analysis
3
Gynecologic and Obstetric Investigation. How Often Are Endometrial Polyps Malignant?
4
PubMed. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps
5
PubMed. Risk and predictors of malignancy in women with endometrial polyps
6
PubMed. Endometrial polyps in postmenopausal women
7
PubMed Central. Malignancy risk factors based on endometrial polyp
8
PubMed. Endometrial Polyp Size and the Risk of Malignancy in Asymptomatic Postmenopausal Women
9
JAMA Network Open. Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
10
PubMed Central. The effect of tamoxifen on the genital tract – Section: Endometrial polyps
11
PubMed. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients
12
Human Reproduction Update. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods
13
International Journal of Gynecology & Obstetrics. Prevalence and risk factors for malignancy in hysteroscopy‐resected endometrial polyps
14
PubMed. Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)
15
Ultrasound in Obstetrics & Gynecology. Flow differences between endometrial polyps and cancer: a prospective study using intravenous contrast‐enhanced transvaginal color flow Doppler and three‐dimensional power Doppler ultrasound
16
Revista Latinoamericana de Hipertensión. The role of transvaginal and Doppler ultrasound in differentiating benign from malignant endometrial pathologies in women with postmenopausal bleeding
17
PubMed Central. Endometrial polyps: Is the prediction of spontaneous regression possible?
18
Human Reproduction. The natural history of endometrial polyps
19
PubMed. To treat or not to treat? An evidence-based practice guide for the management of endometrial polyps
20
PubMed. Endometrial polyps. An evidence-based diagnosis and management guide
21
PubMed. Guideline No. 447: Diagnosis and Management of Endometrial Polyps
22
Human Pathology. The significance of recurrence in endometrial polyps: a clinicopathologic analysis
23
PubMed Central. Comprehensive Analysis of Risk Factors for Recurrence in Women of Reproductive Age Undergoing Hysteroscopic Polypectomy
24
PubMed Central. Assessment of Long- and Short-Term Outcomes of Hysteroscopic Polypectomy in Patients with Uterine Polyps
25
PubMed Central. Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps: A comparison between benign and malignant polyps in postmenopausal patients
26
Genome Medicine. Genomic landscape of endometrial polyps
27
PubMed Central. The management of polyps in female reproductive organs